Melanoma-free Survival
Melanoma-free Survival - Related Videos
09:52
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
0 Views •
Cited by 23 •
2015
Here, we present a protocol how to perform an isolated liver perfusion (IHP) with melphalan and we also discuss IHP as a treatment option for liver metastases of uveal melanoma.
03:52
Experimental Metastatic Melanoma Mouse Model: A Platform to Study the Metastatic Potential of Melanoma Cells in the Lungs
0 Views •
2023
In this video, melanoma cells are intravenously injected through the tail vein in the mouse model. The melanoma cells further travel through the circulatory system, adapting to the distant microenvironment and causing metastasis in organs like lungs.
10:23
Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model
0 Views •
Cited by 32 •
2012
A rapid way to screen for melanoma modifiers using a zebrafish autochthonous tumor model is presented. It takes advantage of the miniCoopR vector which allows for expression of candidate melanoma genes in melanocytes. A method to obtain melanoma-free survival curves, an invasion assay, a protocol for antibody staining of scale melanocytes and a melanoma transplantation assay are described.
12:16
Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
0 Views •
Cited by 22 •
2013
This article describes the preparation of freshly obtained melanoma tissue into primary cell cultures, and how to remove contaminations of erythrocytes and fibroblasts from the tumor cells. Finally, we describe how CD133+ putative melanoma stem cells are sorted from the CD133- bulk using Magnetic Activated Cell Sorting (MACS).
05:40
Melanoma Stem Cell Isolation: A Method to Obtain CD133 Positive and Negative Melanoma Cells Using Magnetic-activated Cell Sorting
0 Views •
2023
This video describes the technique of isolating CD133 negative and positive melanoma stem cells from a primary melanoma cell line using magnetic-activated cell sorting. The CD133 positive melanoma CSCs are further studied to understand the mechanisms of melanoma tumorigenesis.
FAQs
The estimated outcome depends on which clinical events count as failures. Local recurrence, metastatic disease, and melanoma-related death may each end the measured period, but a study must specify these rules consistently. Changing the event definition can change the apparent recurrence burden and alter comparisons between treatments or patient groups, even when the underlying participant outcomes are unchanged.
Censoring allows researchers to include participants who leave a study, reach its conclusion without an event, or have incomplete follow-up without automatically treating them as failures. Their available observation time still contributes to the analysis. Because censoring rules influence how much follow-up is used, investigators must report them clearly when interpreting melanoma-free survival.
Kaplan-Meier curves estimate how the outcome changes over follow-up while accounting for participants who are censored. The curves can display differences in the timing of recurrence, metastatic disease, or melanoma-related death between groups. Statistical models may complement these curves by formally comparing patient groups or treatments and assessing whether observed differences are meaningful within the study design.
Investigators first define the starting point, eligible participants, qualifying melanoma events, and censoring rules. They then follow participants over time, record recurrences, metastatic disease, deaths, and withdrawals, and apply Kaplan-Meier methods or statistical models to the collected data. The resulting estimates support comparisons across treatments or patient groups, provided the endpoint rules remain consistent.
Researchers use this endpoint when they need to evaluate whether one treatment is associated with longer periods without detectable melanoma than another. The comparison requires the same event definitions, follow-up approach, and analysis methods across groups. Results can inform judgments about therapeutic effectiveness and recurrence risk, but short follow-up may provide less insight into long-term outcomes.
Interpretation should consider what counted as an event, how participants were censored, and how long follow-up continued. A result may reflect differences in local recurrence, metastatic disease, or melanoma-related death, depending on the study design. Consequently, melanoma-free survival can support assessment of long-term outcomes, but it should not be interpreted without the endpoint specifications and follow-up context.